Payment overview · 2025
General Payments
$292.79
8 reported records · 7 companies
Healthcare provider profile · identity verified
Wassim Atassi
Allopathic & Osteopathic Physicians|Internal Medicine · HIGHLAND, IN · NPI 1871533927
Verified facts
What the public records show
CMS Open Payments records show Wassim Atassi received $292.79 in general payments during 2025 across 8 reported records.
INTUITIVE SURGICAL, INC. accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $112.24 | 38.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.00 | 23.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.76 | 11.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.30 | 10.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.97 | 7.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.18 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.34 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.79 | 7 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $112.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1157 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 986 | 213 |
| Amlodipine Besylate | Amlodipine Besylate | 622 | 170 |
| Alprazolam | Alprazolam | 580 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 497 | 115 |
| Gabapentin | Gabapentin | 464 | 102 |
| Furosemide | Furosemide | 448 | 117 |
| Eliquis | Apixaban | 446 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 441 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 82 |
| Sertraline Hcl | Sertraline Hcl | 345 | 59 |
| Lisinopril | Lisinopril | 317 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 310 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 60 |
| Metformin Hcl | Metformin Hcl | 284 | 73 |
| Potassium Chloride | Potassium Chloride | 281 | 56 |
| Donepezil Hcl | Donepezil Hcl | 268 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 70 |
| Omeprazole | Omeprazole | 268 | 77 |
| Memantine Hcl | Memantine Hcl | 266 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 72 |
| Carvedilol | Carvedilol | 229 | 72 |
| Famotidine | Famotidine | 229 | 33 |
| Tramadol Hcl | Tramadol Hcl | 194 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 44 |
| Trazodone Hcl | Trazodone Hcl | 192 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 28 |
| Losartan Potassium | Losartan Potassium | 188 | 62 |
| Entresto | Sacubitril/Valsartan | 186 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 176 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 175 | 43 |
| Lorazepam | Lorazepam | 161 | 20 |
| Allopurinol | Allopurinol | 154 | 37 |
| Spironolactone | Spironolactone | 149 | 39 |
| Pregabalin | Pregabalin | 142 | 32 |
| Levetiracetam | Levetiracetam | 141 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 138 | 48 |
| Prednisone | Prednisone | 130 | 85 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 19 |
| Finasteride | Finasteride | 121 | 20 |
| Mirtazapine | Mirtazapine | 119 | 19 |
| Farxiga | Dapagliflozin Propanediol | 107 | 21 |
| Simvastatin | Simvastatin | 107 | 32 |
| Midodrine Hcl | Midodrine Hcl | 103 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 93 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 92 | 18 |
| Ibuprofen | Ibuprofen | 84 | 25 |
| Bumetanide | Bumetanide | 82 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Novolog Flexpen | Insulin Aspart | 78 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 12 |
| Glimepiride | Glimepiride | 75 | 24 |
| Diazepam | Diazepam | 74 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 23 |
| Xarelto | Rivaroxaban | 74 | 17 |
| Ezetimibe | Ezetimibe | 71 | 22 |
| Labetalol Hcl | Labetalol Hcl | 66 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 16 |
| Azithromycin | Azithromycin | 62 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 21 |
| Gemtesa | Vibegron | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 11 |
| Metformin Hcl Er | Metformin Hcl | 60 | 13 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 58 | 51 |
| Clonidine Hcl | Clonidine Hcl | 58 | 12 |
| Meclizine Hcl | Meclizine Hcl | 56 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 20 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 53 | 17 |
| Cephalexin | Cephalexin | 53 | 29 |
| Bupropion Hcl | Bupropion Hcl | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Creon | Lipase/Protease/Amylase | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 15 |
| Meloxicam | Meloxicam | 51 | 16 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 16 |
| Galantamine Hbr | Galantamine Hbr | 45 | suppressed |
| Irbesartan | Irbesartan | 45 | 19 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Nystatin | Nystatin | 44 | 18 |
| Ondansetron Odt | Ondansetron | 44 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | suppressed |
| Latanoprost | Latanoprost | 43 | 11 |
| Sucralfate | Sucralfate | 43 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 28 |
| Glipizide | Glipizide | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 29 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 29 |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 19 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Xifaxan | Rifaximin | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Lactulose | Lactulose | 30 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Loperamide | Loperamide Hcl | 27 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Phenytoin | Phenytoin | 23 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Atenolol | Atenolol | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 20 |
| Linzess | Linaclotide | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Fentanyl | Fentanyl | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 15 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 12 |
| Arformoterol Tartrate | Arformoterol Tartrate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Renvela | Sevelamer Carbonate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $292.79 · 8 records | INTUITIVE SURGICAL, INC. | AIRSUPRA, Da Vinci Surgical System, MOUNJARO, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error